The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data

Omalizumab is an effective and reliable treatment option for childhood CSU. Urticaria-free or well-controlled status can be achieved in a shorter time by initiating treatment with a 300 mg/4 week regimen. Although this dose may need to be increased in most cases, control can be achieved with a dose of 150 mg/4 weeks in a considerable number of patients.